Fig. 2: DOT cells control CRC growth in vivo.
a, Kinetics of tumor-infiltrating DOT cell numbers, per milligram of SW620 tumor tissue, assessed by human CD45 expression by flow cytometry at day 3 (n = 6 mice), day 7 (n = 7 mice) and day 14 (n = 11 mice) after one infusion with 10 million cells. Data were analyzed by a one-way ANOVA with Tukey’s post hoc test. b, Representative flow cytometry density plots with percentages after gating on alive cells and quantification of percentages (of human CD45+ within alive cells) and numbers of DOT cells in tumor and different organs. Colors represent individual mice (n = 4 mice). c, Experimental layout of in vivo i.v. infused DOT cell treatment in an orthotopic (intracecal injection of SW620 cells) CRC model. d, Representative images and kinetics of in vivo tumor growth, quantified as luciferase signal by IVIS lumina (n = 8 mice per group). Data were analyzed by a repeated-measures two-way ANOVA with Šidák’s multiple-comparisons test. In a, b and d, data are presented as the means ± s.e.m. and correspond to one representative of three independent experiments with similar results.
